(CMPS) Compass Pathways - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NASDAQ (USA) | Market Cap: 1.594m USD | Total Return: 176.9% in 12m
Avg Turnover: 34.4M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Interest Coverage Ratio -35.5 is critical
Altman Z'' -6.61 < 1.0 - financial distress zone
Tailwinds
Rs Leader, Idiosyncratic Leader, Tailwind, Pullback 52w
Compass Pathways plc is a clinical-stage biotechnology firm dedicated to developing psychedelic-based therapies for mental health disorders. The company’s lead candidate, COMP360, is a proprietary formulation of synthetic psilocybin currently undergoing Phase III clinical trials for treatment-resistant depression (TRD). Additionally, the firm is evaluating the compound in Phase II trials for post-traumatic stress disorder (PTSD) and anorexia nervosa.
Operating within the emerging neuropsychiatry sector, Compass Pathways utilizes a business model that integrates drug development with specialized psychological support protocols. Unlike traditional pharmaceutical interventions, this model requires a high degree of clinician involvement during the administration of the therapeutic agent. Investors frequently monitor the progress of these trials as they represent a potential shift in the standard of care for chronic mental health conditions.
Investors can review more detailed financial metrics and pipeline updates for CMPS on ValueRay. Founded in 2020 and headquartered in London, the company transitioned from COMPASS Rx Limited to its current corporate structure to support its expansion into global markets, specifically targeting the United Kingdom and the United States.
- COMP360 Phase III clinical trial results for treatment-resistant depression dictate valuation
- FDA regulatory approval pathway for psilocybin therapy remains primary commercial hurdle
- Cash runway and future equity dilution risks impact long-term investor sentiment
- Potential expansion into PTSD and anorexia nervosa markets diversifies clinical pipeline
- Scalability of supervised administration model affects projected operational profit margins
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.30 > 0.02 and ΔFCF/TA 15.13 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.30 > 3% & CFO -159.5m > Net Income -178.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (93.6m) vs 12m ago 4.98% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -35.52 > 6 (EBITDA TTM -172.1m / Interest Expense TTM 4.85m) |
| A: 0.67 (Total Current Assets 510.9m - Total Current Liabilities 153.8m) / Total Assets 531.7m |
| B: -1.38 (Retained Earnings -731.4m / Total Assets 531.7m) |
| C: -0.40 (EBIT TTM -172.3m / Avg Total Assets 425.4m) |
| D: -3.63 (Book Value of Equity -744.8m / Total Liabilities 205.1m) |
| Altman-Z'' = -6.61 = D |
As of May 28, 2026, the stock is trading at USD 11.85 with a total of 2,855,594 shares traded.
Over the past week, the price has changed by +17.68%,
over one month by +33.30%,
over three months by +71.74% and
over the past year by +176.87%.
Compass Pathways has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy CMPS.
- StrongBuy: 7
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22.2 | 87.3% |
P/B = 4.8785
Revenue TTM = 0.0 USD
EBIT TTM = -172.3m USD
EBITDA TTM = -172.1m USD
Long Term Debt = 50.5m USD (from longTermDebt, last quarter)
Short Term Debt = 2.05m USD (from shortTermDebt, last quarter)
Debt = 55.4m USD (corrected: LT Debt 50.5m + ST Debt 2.05m) + Leases 2.83m
Net Debt = -410.6m USD (calculated: Debt 55.4m - CCE 466.0m)
Enterprise Value = 1.18b USD (1.59b + Debt 55.4m - CCE 466.0m)
Interest Coverage Ratio = -35.52 (Ebit TTM -172.3m / Interest Expense TTM 4.85m)
EV/FCF = -7.42x (Enterprise Value 1.18b / FCF TTM -159.5m)
FCF Yield = -13.48% (FCF TTM -159.5m / Enterprise Value 1.18b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 217k) / Revenue TTM)
Tobins Q-Ratio = 2.22 (Enterprise Value 1.18b / Total Assets 531.7m)
Interest Expense / Debt = 8.76% (Interest Expense 4.85m / Debt 55.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -136.1m (EBIT -172.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.32 (Total Current Assets 510.9m / Total Current Liabilities 153.8m)
Debt / Equity = 0.17 (Debt 55.4m / totalStockholderEquity, last quarter 326.7m)
Debt / EBITDA = 2.39 (negative EBITDA) (Net Debt -410.6m / EBITDA -172.1m)
Debt / FCF = 2.57 (negative FCF - burning cash) (Net Debt -410.6m / FCF TTM -159.5m)
Total Stockholder Equity = 118.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.06% (Net Income -178.9m / Total Assets 531.7m)
RoE = -21.06% (Net Income TTM -178.9m / Total Stockholder Equity 849.9m)
RoCE = -19.13% (EBIT -172.3m / Capital Employed (Equity 849.9m + L.T.Debt 50.5m))
RoIC = -69.10% (negative operating profit) (NOPAT -136.1m / Invested Capital 196.9m)
WACC = 11.59% (E(1.59b)/V(1.65b) * Re(11.75%) + D(55.4m)/V(1.65b) * Rd(8.76%) * (1-Tc(0.21)))
Discount Rate = 11.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 89.89 | Cagr: 20.14%
[DCF] Fair Price = unknown (Cash Flow -159.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.12 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.32 | Chg30d=-3.28% | Revisions=N/A | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.34 | Chg30d=-13.11% | Revisions=-20% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.99 | Chg30d=+17.77% | Revisions=N/A | GrowthEPS=+43.7% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.06 | Chg30d=+11.57% | Revisions=+20% | GrowthEPS=-6.2% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -20%